̽»¨Ö±²¥ ̽»¨Ö±²¥ of Cambridge is to take a leading role in a major national effort to help understand and control the new coronavirus infection (COVID-19) announced today by the Government and the UK’s Chief Scientific Adviser.
Almost one in four of the world’s cases of tuberculosis (TB) are in India and the disease is constantly adapting itself to outwit our medicines. Could the answer lie in targeting not the bacteria but its host, the patient?
̽»¨Ö±²¥ ̽»¨Ö±²¥ of Cambridge has been awarded £2 million from the UK Medical Research Council and the Government of India’s Department for Biotechnology to develop a partnership with the National Institute for Research in Tuberculosis (NIRT) in Chennai.
Members of the ̽»¨Ö±²¥ have been recognised for their outstanding contributions to society.
Whole genome sequencing of MRSA from a hospital in Asia has demonstrated patterns of transmission in a resource-limited setting, where formal screening procedures are not feasible.
Centre will support researchers working in public health and tropical medicine.
Researchers have identified a novel mechanism whereby the organism Burkholderia pseudomallei that causes melioidosis, a neglected tropical infectious disease, develops resistance to the standard antibiotic treatment.
Work in resource-restricted healthcare settings in south-east Asia is defining the transmission of hospital ‘superbugs’ using low-tech diagnostics and high-tech tools.
̽»¨Ö±²¥expertise of Cambridge's new Professor of Clinical Microbiology, Sharon Peacock, is helping to drive a programme of research that will track and block routes of transmission for superbugs.
© 2025 ̽»¨Ö±²¥ of Cambridge